Clinical trials: Cancer Progression
Bladder Cancer
First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC
The purpose of this study is to compare the safety and efficacy of EN3348 (MCC) versus BCG as first line treatment in patients with non-muscle invasive bladder cancer that are at high risk for recurrence or progression.
- Trial name
- NCT01284205
- Testing
- Mycobacterial Cell-Wall DNA Complex, Bacillus Calmette-Guerin
- Where
- 14 sites in United States
- Sponsor
- Bioniche Life Sciences Inc.
Interstitial Lung Diseases
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
This study is open to adults with fibrosing interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). People can join the study if they have been diagnosed with this condition within the last 3 years and are…
- Trial name
- NCT07540988
- Testing
- Nerandomilast
- Where
- 162 sites in United States, Argentina and 18 more
- Volunteers
- 466 people
- Sponsor
- Boehringer Ingelheim
Breast Cancer, Neoplasm Metastasis
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
The purpose of this study is to assess the impact on tumor progression as evaluated by progression-free survival (PFS) of epoetin alfa plus standard supportive care as compared with standard supportive care alone (packed red…
- Trial name
- NCT00338286
- Testing
- Standard supportive care (packed RBC transfusion), epoetin alfa + packed RBC transfusion
- Where
- 174 sites in United States, Argentina and 19 more
- Volunteers
- 2,098 people
- Sponsor
- Janssen Research & Development, LLC
T2DM (Type 2 Diabetes Mellitus), CKD - Chronic Kidney Disease
Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
This study aims to investigate the impact of adding Ganagliflozin tablets to the current background therapy on preventing the progression of kidney disease in subjects with type 2 diabetes and chronic kidney disease.
- Trial name
- GLOW-CKD (NCT07116928)
- Testing
- ganagliflozin
- Where
- China
- Volunteers
- 1,244 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Type 1 Diabetes
Efficacy and Safety of Diamyd® in Children and Adolescents With Type 1 Diabetes
This is a randomized, placebo-controlled phase II study to investigate if a prime and boost of 20ug Diamyd® (rhGAD65 formulated in Alhydrogel®), administered subcutaneously four weeks apart, is safe and can preserve beta cell…
- Trial name
- NCT00435981
- Testing
- rhGAD65 formulated in Alhydrogel® (Diamyd®)
- Where
- 8 sites in Sweden
- Volunteers
- 70 people
- Sponsor
- Diamyd Therapeutics AB
PreDiabetes, Myocardial Infarction
Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction
It is hypothesize that, because dapagliflozin will reverse the metabolic defects responsible for the development of prediabetes (i.e.
- Conditions
- PreDiabetes, Myocardial Infarction, T2DM (Type 2 Diabetes Mellitus), CVD
- Trial name
- NCT03658031
- Testing
- Dapagliflozin 10mg
- Where
- Qatar
- Volunteers
- 576 people
- Sponsor
- Hamad Medical Corporation
Prostate Cancer
Observational Retrospective Trial on Sequential Hormonal Therapy in Patients With Prostate Cancer
Observational Retrospective trial on sequential hormonal therapy in patients with Prostate Cancer
- Trial name
- Sorse (NCT00668083)
- Where
- 12 sites in Italy
- Volunteers
- 214 people
- Sponsor
- AstraZeneca
Metastatic Melanoma, Unresectable Melanoma
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
Phase 3, multicenter, international, open-label, randomized, 2-arm trial investigating the safety and efficacy of IO102-IO103 in combination with pembrolizumab as first-line treatment for patients with previously untreated…
- Trial name
- NCT05155254
- Testing
- IO102-IO103, Pembrolizumab
- Where
- 112 sites in United States, Australia and 14 more
- Volunteers
- 407 people
- Sponsor
- IO Biotech
Renal Cell Carcinoma
Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2.
Non-interventional study. Data obtained by patient chart reviews. Retrospective analysis of progression free survival, time to treatment failure and overall survival in a national cohort of patients with metastatic renal cell…
- Trial name
- NCT01339962
- Testing
- Non-interventional
- Where
- Denmark
- Volunteers
- 1,073 people
- Sponsor
- Pfizer
Metastatic Non-Squamous Non-Small Cell Lung Cancer
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or…
- Trial name
- SAPPHIRE (NCT03906071)
- Testing
- Nivolumab, Sitravatinib, Docetaxel
- Where
- 261 sites in United States, Belgium and 10 more
- Volunteers
- 577 people
- Sponsor
- Mirati Therapeutics Inc.
Psoriatic Arthritis
Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis
The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis.
- Trial name
- AMVISION-1 (NCT02029495)
- Testing
- 210 mg brodalumab, 140 mg brodalumab
- Where
- 152 sites in United States, Belgium and 15 more
- Volunteers
- 478 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Bronchitis, Disease Exacerbation
VICTOR - Avelox® Intravenous (i.v.) in Acute Exacerbations of Chronic Bronchitis
This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from an acute exacerbation of chronic bronchitis and take at least one dose of…
- Trial name
- VICTOR (NCT00876577)
- Testing
- Moxifloxacin (Avelox, BAY12-8039)
- Where
- China
- Volunteers
- 1,206 people
- Sponsor
- Bayer
Breast Cancer
Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.
The purpose of this study is determine if the triplet combination of ribociclib, everolimus and exemastane is safe and effective in the treatment of locally advanced/metastatic breast cancer following treatment with a CDK 4/6…
- Trial name
- TRINITI-1 (NCT02732119)
- Testing
- Ribociclib, Everolimus, Exemestane
- Where
- 25 sites in United States
- Volunteers
- 104 people
- Sponsor
- Novartis Pharmaceuticals
Myopia
MyopiaX Treatment for the Reduction of Myopia Progression in Children and Adolescents: Safety and Efficacy Investigation
The purpose of this trial is to investigate the safety and efficacy of MyopiaX - a digital treatment intended to slow the progression of myopia in children and adolescents.
- Trial name
- MyopiaX-1 (NCT04967287)
- Testing
- MyopiaX, Myopia control spectacles
- Where
- 10 sites in Germany, Netherlands and 3 more
- Volunteers
- 124 people
- Sponsor
- Dopavision GmbH
Diabetic Kidney Disease (DKD)
Rubix LS Diabetic Kidney Disease (DKD) Registry Study
Diabetic kidney disease (DKD) is a common complication of type 2 diabetes that can lead to kidney failure and increases the risk of cardiovascular disease.
- Trial name
- NCT07348718
- Testing
- Kidney-Protective Therapies Used in Routine Care
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Rubix LS
Dry Age-related Macular Degeneration, Macular Degeneration
GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)
An observational study to evaluate the natural progression of dry AMD in genetically defined subjects
- Conditions
- Dry Age-related Macular Degeneration, Macular Degeneration, Retinal Disease, Retinal Degeneration
- Trial name
- NCT03894020
- Where
- 71 sites in United States, Australia and 6 more
- Volunteers
- 83 people
- Sponsor
- Gyroscope Therapeutics Limited
Carcinoma, Non-Small-Cell Lung
KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy
This study involves treatment with KD019 or erlotinib in patients with Non-small cell lung cancer (NSCLC) who have progressed after first- or second- line chemotherapy.
- Trial name
- NCT01487174
- Testing
- KD019, Erlotinib
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Kadmon Corporation, LLC
Glioblastoma
Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression
Open label phase I study in subjects with glioblastoma at first progression to explore two different administration schedules of lomustine for the combination with L19TNF (ARM 1 and ARM 2).
- Trial name
- GLIOASTRA (NCT05304663)
- Testing
- Onfekafusp alfa, Lomustine
- Sponsor
- Philogen S.p.A.
Duchenne Muscular Dystrophy
A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy.
To characterize the natural history and progression of Duchenne Muscular Dystrophy (DMD) to help inform the design of future studies, to capture biomarkers of safety and disease progression and to provide comparative data for the…
- Trial name
- NCT01753804
- Testing
- Observational study
- Where
- 16 sites in United States, Argentina and 8 more
- Volunteers
- 269 people
- Sponsor
- BioMarin Pharmaceutical
Complete Remission in Renal Cell Carcinoma
Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients
This prospective study will investigate the characteristics of mRCC patients at time of CR in comparison with mRCC patients non on CR treated with Sunitinib, in order to provide some answers/ refection leads to the following…
- Trial name
- APERCU (NCT01934452)
- Testing
- sunitinib
- Where
- 14 sites in France
- Volunteers
- 77 people
- Sponsor
- Pfizer